Literature DB >> 26115445

Association of IFNL3 and IFNL4 polymorphisms with liver-related mortality in a multiracial cohort of HIV/HCV-coinfected women.

M Sarkar1, B Aouzierat2, P Bacchetti3, L Prokunina-Olsson4, A French5, E Seaberg6, T R O'Brien7, M H Kuniholm8, H Minkoff9, M Plankey10, H D Strickler8, M G Peters1.   

Abstract

African Americans coinfected with HIV and hepatitis C virus (HCV) have lower liver-related mortality than Caucasians and Hispanics. While genetic polymorphisms near the IFNL3 and IFNL4 genes explain a significant fraction of racial differences in several HCV-related outcomes, the impact of these variants on liver-related mortality has not been investigated. We conducted a cohort study of HIV/HCV-coinfected women followed in the multicentre, NIH-funded Women's Interagency HIV Study (WIHS) to investigate whether 10 polymorphisms spanning the IFN-λ region were associated with liver-related mortality by dominant, recessive or additive genetic models. We also considered whether these polymorphisms contributed to previously reported differences in liver-related death by race/ethnicity (ascertained by self-report and ancestry informative markers). Among 794 coinfected women, there were 471 deaths including 55 liver-related deaths during up to 18 years of follow-up. On adjusted analysis, rs12980275 GG genotype compared to AG+AA hazards ratios [(HR) 0.36, 95% CI 0.14-0.90, P = 0.029] and rs8109886 AA genotype compared to CC+AC (HR 0.67, 95% CI 0.45-0.99, P = 0.047) were most strongly associated with liver-related death although these associations were no longer significant after adjusting for race/ethnicity (HR 0.41, 95% CI 0.16-1.04, P = 0.060 and HR 0.78, 95% CI 0.51-1.19, P = 0.25, respectively). African American women had persistently lower liver-related death independent of IFN-λ variants (HRs ≤ 0.44, P values ≤ 0.04). The lower risk of death among African American HIV/HCV-coinfected women is not explained by genetic variation in the IFN-λ region suggesting, that other genetic, behavioural and/or environmental factors may contribute to racial/ethnic differences in liver-related mortality.
© 2015 John Wiley & Sons Ltd.

Entities:  

Keywords:  death; ethnicity; genetic, interferon-λ; polymorphisms

Mesh:

Substances:

Year:  2015        PMID: 26115445      PMCID: PMC4618098          DOI: 10.1111/jvh.12431

Source DB:  PubMed          Journal:  J Viral Hepat        ISSN: 1352-0504            Impact factor:   3.728


  22 in total

1.  Genetic variation in the interleukin-28B gene is not associated with fibrosis progression in patients with chronic hepatitis C and known date of infection.

Authors:  Francesco Marabita; Alessio Aghemo; Stella De Nicola; Maria G Rumi; Cristina Cheroni; Rossana Scavelli; Marco Crimi; Roberta Soffredini; Sergio Abrignani; Raffaele De Francesco; Massimo Colombo
Journal:  Hepatology       Date:  2011-08-19       Impact factor: 17.425

2.  IL28B alleles associated with poor hepatitis C virus (HCV) clearance protect against inflammation and fibrosis in patients infected with non-1 HCV genotypes.

Authors:  Pierre-Yves Bochud; Stéphanie Bibert; Zoltán Kutalik; Etienne Patin; Julien Guergnon; Bertrand Nalpas; Nicolas Goossens; Lorenz Kuske; Beat Müllhaupt; Tillman Gerlach; Markus H Heim; Darius Moradpour; Andreas Cerny; Raffaele Malinverni; Stephan Regenass; Guenter Dollenmaier; Hans Hirsch; Gladys Martinetti; Meri Gorgiewski; Marc Bourlière; Thierry Poynard; Ioannis Theodorou; Laurent Abel; Stanislas Pol; Jean-François Dufour; Francesco Negro
Journal:  Hepatology       Date:  2011-12-16       Impact factor: 17.425

3.  A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus.

Authors:  Ludmila Prokunina-Olsson; Brian Muchmore; Wei Tang; Ruth M Pfeiffer; Heiyoung Park; Harold Dickensheets; Dianna Hergott; Patricia Porter-Gill; Adam Mumy; Indu Kohaar; Sabrina Chen; Nathan Brand; McAnthony Tarway; Luyang Liu; Faruk Sheikh; Jacquie Astemborski; Herbert L Bonkovsky; Brian R Edlin; Charles D Howell; Timothy R Morgan; David L Thomas; Barbara Rehermann; Raymond P Donnelly; Thomas R O'Brien
Journal:  Nat Genet       Date:  2013-01-06       Impact factor: 38.330

Review 4.  Models of care for the management of hepatitis C virus among people who inject drugs: one size does not fit all.

Authors:  Philip Bruggmann; Alain H Litwin
Journal:  Clin Infect Dis       Date:  2013-08       Impact factor: 9.079

5.  Association of the IFNL4-ΔG Allele With Impaired Spontaneous Clearance of Hepatitis C Virus.

Authors:  Peter V Aka; Mark H Kuniholm; Ruth M Pfeiffer; Alan S Wang; Wei Tang; Sabrina Chen; Jacquie Astemborski; Michael Plankey; Maria C Villacres; Marion G Peters; Seema Desai; Eric C Seaberg; Brian R Edlin; Howard D Strickler; David L Thomas; Ludmila Prokunina-Olsson; Gerald B Sharp; Thomas R O'Brien
Journal:  J Infect Dis       Date:  2013-08-15       Impact factor: 5.226

6.  Comorbidity-related treatment outcomes among HIV-infected adults in the Bronx, NY.

Authors:  Carolyn Chu; Galina Umanski; Arthur Blank; Paul Meissner; Robert Grossberg; Peter A Selwyn
Journal:  J Urban Health       Date:  2011-06       Impact factor: 3.671

7.  Association of IL28B genotype with fibrosis progression and clinical outcomes in patients with chronic hepatitis C: a longitudinal analysis.

Authors:  Mazen Noureddin; Elizabeth C Wright; Harvey J Alter; Shauna Clark; Emmanuel Thomas; Richard Chen; Xiongce Zhao; Cathy Conry-Cantilena; David E Kleiner; T Jake Liang; Marc G Ghany
Journal:  Hepatology       Date:  2013-09-30       Impact factor: 17.425

8.  Chronic hepatitis C virus infection in the United States, National Health and Nutrition Examination Survey 2003 to 2010.

Authors:  Maxine M Denniston; Ruth B Jiles; Jan Drobeniuc; R Monina Klevens; John W Ward; Geraldine M McQuillan; Scott D Holmberg
Journal:  Ann Intern Med       Date:  2014-03-04       Impact factor: 25.391

9.  Progression of liver fibrosis in HIV/HCV genotype 1 co-infected patients is related to the T allele of the rs12979860 polymorphism of the IL28B gene.

Authors:  P Lutz; J-C Wasmuth; H-D Nischalke; N Vidovic; F Grünhage; F Lammert; J Oldenburg; J K Rockstroh; T Sauerbruch; Ulrich Spengler
Journal:  Eur J Med Res       Date:  2011-08-08       Impact factor: 2.175

10.  Role of interleukin 28B rs12979860 C/T polymorphism on the histological outcome of chronic hepatitis C: relationship with gender and viral genotype.

Authors:  Edmondo Falleti; Davide Bitetto; Carlo Fabris; Annarosa Cussigh; Ezio Fornasiere; Sara Cmet; Elisa Fumolo; Sara Bignulin; Elisabetta Fontanini; Andrea Cerutti; Rosalba Minisini; Mario Pirisi; Pierluigi Toniutto
Journal:  J Clin Immunol       Date:  2011-06-07       Impact factor: 8.542

View more
  3 in total

1.  Macrophage Activation and the Tumor Necrosis Factor Cascade in Hepatitis C Disease Progression Among HIV-Infected Women Participating in the Women's Interagency HIV Study.

Authors:  Audrey L French; Jonathan W Martin; Charlesnika T Evans; Marion Peters; Seble G Kessaye; Marek Nowicki; Mark Kuniholm; Elizabeth Golub; Michael Augenbraun; Seema N Desai
Journal:  J Acquir Immune Defic Syndr       Date:  2017-12-01       Impact factor: 3.731

2.  Racial differences in human papilloma virus types amongst United States women with HIV and cervical precancer.

Authors:  Marla J Keller; Robert D Burk; L Stewart Massad; Isam-Eldin Eltoum; Nancy A Hessol; Kathryn Anastos; Xianhong Xie; Howard Minkoff; Xiaonan Xue; Laura L Reimers; Mark Kuniholm; Gypsyamber DʼSouza; Christine Colie; Bradley Aouizerat; Joel M Palefsky; Howard D Strickler
Journal:  AIDS       Date:  2018-11-28       Impact factor: 4.632

3.  A genomic variant of ALPK2 is associated with increased liver fibrosis risk in HIV/HCV coinfected women.

Authors:  Alec T McIntosh; Renhuizi Wei; Jaeil Ahn; Brad E Aouizerat; Seble G Kassaye; Michael H Augenbraun; Jennifer C Price; Audrey L French; Stephen J Gange; Kathryn M Anastos; Radoslav Goldman
Journal:  PLoS One       Date:  2021-03-11       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.